Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Non-Current Debt (2020 - 2025)

Gain Therapeutics (GANX) has 6 years of Non-Current Debt data on record, last reported at $298797.0 in Q3 2025.

  • For Q3 2025, Non-Current Debt fell 20.56% year-over-year to $298797.0; the TTM value through Sep 2025 reached $298797.0, down 20.56%, while the annual FY2024 figure was $328327.0, 26.88% down from the prior year.
  • Non-Current Debt reached $298797.0 in Q3 2025 per GANX's latest filing, down from $325359.0 in the prior quarter.
  • Across five years, Non-Current Debt topped out at $678255.0 in Q1 2021 and bottomed at $298797.0 in Q3 2025.
  • Average Non-Current Debt over 5 years is $466430.8, with a median of $466638.0 recorded in 2023.
  • Peak YoY movement for Non-Current Debt: decreased 9.33% in 2023, then decreased 26.88% in 2024.
  • A 5-year view of Non-Current Debt shows it stood at $590468.0 in 2021, then decreased by 16.12% to $495258.0 in 2022, then fell by 9.33% to $449053.0 in 2023, then decreased by 26.88% to $328327.0 in 2024, then fell by 8.99% to $298797.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Debt were $298797.0 in Q3 2025, $325359.0 in Q2 2025, and $314476.0 in Q1 2025.